Actelion boosted by selexipag data
This article was originally published in Scrip
Executive Summary
Actelion's share price closed up by 2.45% at CHF117.00 on 16 March after the firm announced positive long-term outcome data from a pivotal trial of its investigational oral prostacyclin agonist selexipag for pulmonary arterial hypertension (PAH). The data from the 1,156-patient Phase III GRIPHON study showed that selexipag reduced the risk of a morbidity/mortality event by 40% versus placebo (p<0.0001)>